{"id":59340,"date":"2026-03-12T13:27:15","date_gmt":"2026-03-12T05:27:15","guid":{"rendered":"https:\/\/flcube.com\/?p=59340"},"modified":"2026-03-12T13:27:16","modified_gmt":"2026-03-12T05:27:16","slug":"sino-biopharms-tqb3205-wins-nmpa-approval-first-china-developed-pan-kras-inhibitor-enters-clinic-for-advanced-cancers","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59340","title":{"rendered":"Sino Biopharm&#8217;s TQB3205 Wins NMPA Approval \u2013 First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers"},"content":{"rendered":"\n<p><strong>Sino Biopharmaceutical Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>) announced that <strong>TQB3205<\/strong>, an <strong>orally administered Pan-KRAS inhibitor<\/strong> independently developed by subsidiary <strong>Chia Tai Tianqing Pharmaceutical Group (CTTQ)<\/strong>, has received <strong>first-time NMPA clinical trial approval<\/strong> for the treatment of <strong>advanced malignant tumors<\/strong>. The <strong>novel small molecule<\/strong> achieves <strong>high-affinity binding with various KRAS mutant proteins<\/strong>, blocking <strong>SOS1-mediated nucleotide exchange<\/strong> and suppressing <strong>ERK phosphorylation downstream of KRAS<\/strong>, representing a <strong>next-generation approach<\/strong> to targeting the <strong>historically undruggable KRAS oncogene<\/strong> across <strong>multiple mutation subtypes<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>First-time clinical trial authorization (IND)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>TQB3205<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Orally administered Pan-KRAS inhibitor (small molecule)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced malignant tumors<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Chia Tai Tianqing Pharmaceutical Group (CTTQ) \u2013 Sino Biopharmaceutical subsidiary (HKG: 1177)<\/td><\/tr><tr><td><strong>Development Status<\/strong><\/td><td>First China-developed Pan-KRAS inhibitor to enter clinical trials<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>10\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>TQB3205 Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Target Class<\/strong><\/td><td>Pan-KRAS (multiple KRAS mutant proteins)<\/td><\/tr><tr><td><strong>Binding Mechanism<\/strong><\/td><td>High-affinity binding with various KRAS mutant proteins<\/td><\/tr><tr><td><strong>Molecular Action<\/strong><\/td><td>Inhibits SOS1-mediated KRAS nucleotide exchange<\/td><\/tr><tr><td><strong>Downstream Effect<\/strong><\/td><td>Suppresses ERK phosphorylation (MAPK pathway blockade)<\/td><\/tr><tr><td><strong>Clinical Outcome<\/strong><\/td><td>Inhibits proliferation of KRAS mutant tumor cells; target-level anti-tumor effects<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Oral administration<\/td><\/tr><tr><td><strong>Innovation Class<\/strong><\/td><td>Next-generation KRAS targeting (beyond G12C-specific inhibitors)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Scientific Rationale:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>KRAS Mutations:<\/strong> Present in ~25% of all cancers; G12C, G12D, G12V, G13D subtypes drive oncogenesis<\/li>\n\n\n\n<li><strong>SOS1 Inhibition:<\/strong> Blocks guanine nucleotide exchange factor (GEF) activity \u2192 traps KRAS in inactive GDP-bound state<\/li>\n\n\n\n<li><strong>Pan-KRAS Advantage:<\/strong> Addresses multiple mutant alleles vs. single-mutation inhibitors (sotorasib, adagrasib limited to G12C)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-market-opportunity\">Strategic Context &amp; Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>KRAS Market Evolution<\/strong><\/td><td>Sotorasib\/adagrasib (G12C only) approved 2021-2022; limited by narrow mutation coverage; resistance common<\/td><\/tr><tr><td><strong>Pan-KRAS Unmet Need<\/strong><\/td><td>G12D (pancreatic, colorectal) and other mutations lack effective targeted therapy; TQB3205 addresses broader population<\/td><\/tr><tr><td><strong>China Innovation<\/strong><\/td><td>First domestic Pan-KRAS inhibitor validates Sino Biopharm\/CTTQ discovery capabilities; global competitiveness<\/td><\/tr><tr><td><strong>Oral Convenience<\/strong><\/td><td>Small molecule oral vs. injectable biologics; improved patient compliance<\/td><\/tr><tr><td><strong>Combination Potential<\/strong><\/td><td>SOS1 inhibition synergistic with MEK, EGFR, or immunotherapy in KRAS-driven tumors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Mechanism<\/th><th>Mutation Coverage<\/th><th>Status<\/th><th>TQB3205 Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Amgen<\/strong><\/td><td>Lumakras (sotorasib)<\/td><td>KRAS G12C inhibitor<\/td><td>G12C only<\/td><td>Approved (NSCLC, colorectal)<\/td><td>Pan-KRAS vs. single mutation; addresses resistance<\/td><\/tr><tr><td><strong>Mirati\/BMS<\/strong><\/td><td>Krazati (adagrasib)<\/td><td>KRAS G12C inhibitor<\/td><td>G12C only<\/td><td>Approved (NSCLC)<\/td><td>Broader mutation coverage; SOS1 mechanism<\/td><\/tr><tr><td><strong>Revolution\/Sanofi<\/strong><\/td><td>RMC-6236<\/td><td>RAS(ON) inhibitor (pan-RAS)<\/td><td>Multiple RAS isoforms<\/td><td>Phase I\/II<\/td><td>TQB3205 KRAS-specific vs. pan-RAS; potentially better tolerability<\/td><\/tr><tr><td><strong>Sino Biopharm\/CTTQ<\/strong><\/td><td><strong>TQB3205<\/strong><\/td><td><strong>Pan-KRAS inhibitor (SOS1-mediated)<\/strong><\/td><td><strong>Multiple KRAS mutants<\/strong><\/td><td><strong>Phase I-ready<\/strong><\/td><td><strong>First China-developed; oral; SOS1 mechanism<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-outlook\">Development Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Timeline<\/th><th>Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase I<\/strong><\/td><td>2026-2027<\/td><td>Safety, tolerability, MTD; pharmacokinetics; biomarker-defined KRAS mutant enrollment<\/td><\/tr><tr><td><strong>Phase II<\/strong><\/td><td>2027-2029<\/td><td>Efficacy signals in pancreatic, colorectal, lung cancers; mutation-specific cohorts<\/td><\/tr><tr><td><strong>Phase III<\/strong><\/td><td>2029-2031<\/td><td>Registrational studies vs. chemotherapy in KRAS G12D pancreatic cancer (high unmet need)<\/td><\/tr><tr><td><strong>Global Strategy<\/strong><\/td><td>2028+<\/td><td>U.S.\/EU IND filing; partnership discussions for ex-China rights; combination study initiation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, Pan-KRAS mechanism validation, and competitive positioning for TQB3205. Actual results may differ due to KRAS biology complexity, SOS1 inhibition tolerability, and competitive dynamics with G12C inhibitors and emerging pan-RAS approaches.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sino Biopharmaceutical Limited (HKG: 1177) announced that TQB3205, an orally administered Pan-KRAS inhibitor independently developed&#8230;<\/p>\n","protected":false},"author":1,"featured_media":59341,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[661,62,908,313],"class_list":["post-59340","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-chia-tai-tianqing-pharmaceutical","tag-clinical-trial-approval-initiation","tag-hkg-1177","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharm&#039;s TQB3205 Wins NMPA Approval \u2013 First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino Biopharmaceutical Limited (HKG: 1177) announced that TQB3205, an orally administered Pan-KRAS inhibitor independently developed by subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), has received first-time NMPA clinical trial approval for the treatment of advanced malignant tumors. The novel small molecule achieves high-affinity binding with various KRAS mutant proteins, blocking SOS1-mediated nucleotide exchange and suppressing ERK phosphorylation downstream of KRAS, representing a next-generation approach to targeting the historically undruggable KRAS oncogene across multiple mutation subtypes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59340\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharm&#039;s TQB3205 Wins NMPA Approval \u2013 First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers\" \/>\n<meta property=\"og:description\" content=\"Sino Biopharmaceutical Limited (HKG: 1177) announced that TQB3205, an orally administered Pan-KRAS inhibitor independently developed by subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), has received first-time NMPA clinical trial approval for the treatment of advanced malignant tumors. The novel small molecule achieves high-affinity binding with various KRAS mutant proteins, blocking SOS1-mediated nucleotide exchange and suppressing ERK phosphorylation downstream of KRAS, representing a next-generation approach to targeting the historically undruggable KRAS oncogene across multiple mutation subtypes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59340\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-12T05:27:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-12T05:27:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1203.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59340#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59340\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharm&#8217;s TQB3205 Wins NMPA Approval \u2013 First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers\",\"datePublished\":\"2026-03-12T05:27:15+00:00\",\"dateModified\":\"2026-03-12T05:27:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59340\"},\"wordCount\":531,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59340#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1203.webp\",\"keywords\":[\"Chia Tai Tianqing Pharmaceutical\",\"Clinical trial approval \\\/ initiation\",\"HKG: 1177\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59340#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59340\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59340\",\"name\":\"Sino Biopharm's TQB3205 Wins NMPA Approval \u2013 First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59340#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59340#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1203.webp\",\"datePublished\":\"2026-03-12T05:27:15+00:00\",\"dateModified\":\"2026-03-12T05:27:16+00:00\",\"description\":\"Sino Biopharmaceutical Limited (HKG: 1177) announced that TQB3205, an orally administered Pan-KRAS inhibitor independently developed by subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), has received first-time NMPA clinical trial approval for the treatment of advanced malignant tumors. The novel small molecule achieves high-affinity binding with various KRAS mutant proteins, blocking SOS1-mediated nucleotide exchange and suppressing ERK phosphorylation downstream of KRAS, representing a next-generation approach to targeting the historically undruggable KRAS oncogene across multiple mutation subtypes.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59340#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59340\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59340#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1203.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1203.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sino Biopharm's TQB3205 Wins NMPA Approval \u2013 First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59340#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharm&#8217;s TQB3205 Wins NMPA Approval \u2013 First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharm's TQB3205 Wins NMPA Approval \u2013 First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers - Insight, China&#039;s Pharmaceutical Industry","description":"Sino Biopharmaceutical Limited (HKG: 1177) announced that TQB3205, an orally administered Pan-KRAS inhibitor independently developed by subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), has received first-time NMPA clinical trial approval for the treatment of advanced malignant tumors. The novel small molecule achieves high-affinity binding with various KRAS mutant proteins, blocking SOS1-mediated nucleotide exchange and suppressing ERK phosphorylation downstream of KRAS, representing a next-generation approach to targeting the historically undruggable KRAS oncogene across multiple mutation subtypes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59340","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharm's TQB3205 Wins NMPA Approval \u2013 First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers","og_description":"Sino Biopharmaceutical Limited (HKG: 1177) announced that TQB3205, an orally administered Pan-KRAS inhibitor independently developed by subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), has received first-time NMPA clinical trial approval for the treatment of advanced malignant tumors. The novel small molecule achieves high-affinity binding with various KRAS mutant proteins, blocking SOS1-mediated nucleotide exchange and suppressing ERK phosphorylation downstream of KRAS, representing a next-generation approach to targeting the historically undruggable KRAS oncogene across multiple mutation subtypes.","og_url":"https:\/\/flcube.com\/?p=59340","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-12T05:27:15+00:00","article_modified_time":"2026-03-12T05:27:16+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1203.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59340#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59340"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharm&#8217;s TQB3205 Wins NMPA Approval \u2013 First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers","datePublished":"2026-03-12T05:27:15+00:00","dateModified":"2026-03-12T05:27:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59340"},"wordCount":531,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59340#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1203.webp","keywords":["Chia Tai Tianqing Pharmaceutical","Clinical trial approval \/ initiation","HKG: 1177","Sino Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59340#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59340","url":"https:\/\/flcube.com\/?p=59340","name":"Sino Biopharm's TQB3205 Wins NMPA Approval \u2013 First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59340#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59340#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1203.webp","datePublished":"2026-03-12T05:27:15+00:00","dateModified":"2026-03-12T05:27:16+00:00","description":"Sino Biopharmaceutical Limited (HKG: 1177) announced that TQB3205, an orally administered Pan-KRAS inhibitor independently developed by subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), has received first-time NMPA clinical trial approval for the treatment of advanced malignant tumors. The novel small molecule achieves high-affinity binding with various KRAS mutant proteins, blocking SOS1-mediated nucleotide exchange and suppressing ERK phosphorylation downstream of KRAS, representing a next-generation approach to targeting the historically undruggable KRAS oncogene across multiple mutation subtypes.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59340#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59340"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59340#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1203.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1203.webp","width":1080,"height":608,"caption":"Sino Biopharm's TQB3205 Wins NMPA Approval \u2013 First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59340#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharm&#8217;s TQB3205 Wins NMPA Approval \u2013 First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1203.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59340"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59340\/revisions"}],"predecessor-version":[{"id":59342,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59340\/revisions\/59342"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59341"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}